Deciding When and How to Suspend Trials: Guidance from Industry Experts and the FDA

As the medical community shifts much of its focus — and its resources — to battling the ongoing COVID-19 pandemic, clinical trial sponsors and sites are left wondering what to do about ongoing drug and device studies unrelated to the coronavirus. Which studies should be paused and which should be allowed to continue? Could modifications to study protocols around data collection and patient visits strike a balance between maintaining both patient safety and the integrity of ongoing trials?